In this webinar, discover how to get the most out of your patient engagement programs while protecting your brand from regulatory non-compliance.

This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.

This all-purpose due diligence checklist contains a list of all the standard documents any buyer or partner might want to see.
.

The Life Sciences due diligence checklist covers unique characteristics applicable to your industry, which buyers or partners may want to examine.

Oncology venture funding, IPOs and partnerships have been exceptionally high in deal volume and values. Cancer continues to be the leading therapeutic area in the number and size of early deals, and the oncology pipeline continues to be a rich source of both follow-on agents as well as first-in-class programs.

2020 was an unprecedented year for Special Purpose Acquisition Corps (SPACs), an alternative public offering (APO) financing vehicle for listing on a public stock exchange.

In this whitepaper, learn what is artificial intelligence and how is it being applied to drug discovery, and much more.

In this whitepaper, you will learn 8 "habits" of highly effective data rooms to ensure your selection facilitates the due diligence process rather than impede it.

This whitepaper provides a strategic perspective coupled with actionable tips to help guide you through the essential steps that will help maximize your chance of achieving success in biopharma partnering.

In this whitepaper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner.

In this whitepaper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.

This white paper covers when to consider using suppliers, key differences between standard / OTS and custom part suppliers, tools and methods for managing suppliers, and when and how to transition between suppliers and internal resources.